Production of recombinant woodchuck IFNalpha and development of monoclonal antibodies
Keywords: 
2',5'-Oligoadenylate Synthetase/drug effects
Antibodies, Monoclonal/biosynthesis
Hepatitis B/immunology
Hepatitis B Antibodies/biosynthesis
Interferon-alpha/immunology
Issue Date: 
2009
Publisher: 
Mary Ann Liebert
ISSN: 
1079-9907
Citation: 
Berraondo P, Crettaz J, Ochoa L, Vales A, Ruiz J, Prieto J, et al. Production of recombinant woodchuck IFNalpha and development of monoclonal antibodies. J Interferon Cytokine Res 2009 Feb;29(2):75-82.
Abstract
Interferon alpha (IFNalpha) is the first line treatment for chronic hepatitis B and C. In order to test new IFNalpha delivery systems and investigate the function of this cytokine in the woodchuck model, the best animal model of chronic hepatitis B, we produced and purified recombinant woodchuck IFNalpha and used it to produce monoclonal antibodies. wIFNalpha5 was cloned in a prokaryotic expression system, expressed as His-tagged protein and then purified. The rwIFNalpha5 protein was found to induce STAT-3 phosphorylation, to enhance 2',5'-oligoadenylate synthetase mRNA levels and to possess a potent antiviral activity. Two monoclonal antibodies were obtained through immunization of rats with rwIFNalpha5. Both recognized rwIFNalpha5 in western blot analysis and one was able to neutralize the antiviral activity of the rwIFNalpha5 and lymphoblastoid IFNalpha preparations. Finally, a capture rwIFNalpha5 ELISA was developed using both antibodies. In summary, the tools generated in this study will allow different forms of IFNalpha delivery as well as different combination therapies in woodchuck hepatitis virus infection to be tested, thus providing useful information for the design of new strategies to treat chronic hepatitis B in humans.

Files in This Item:
Thumbnail
File
jir.2008.0012.pdf
Description
Size
284.52 kB
Format
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.